COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR
申请人:CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
公开号:US20220175917A1
公开(公告)日:2022-06-09
The present invention relates to a combination of a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof which are used as an IAP inhibitor, and an immune checkpoint inhibitor; and use of the combination in the preparation of a cancer treatment drug.
SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF
申请人:Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
公开号:EP3712162A1
公开(公告)日:2020-09-23
Disclosed are a class of SMAC mimetics used as IAP inhibitors, and in particular disclosed are compounds as shown in formula (I), isomers thereof, and pharmaceutically acceptable salts thereof. The IAP inhibitors are drugs for treating cancers, in particular breast cancer.
SMAC mimetics used as IAP inhibitors and use thereof
申请人:CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
公开号:US11358950B2
公开(公告)日:2022-06-14
Disclosed are a class of SMAC mimetics used as IAP inhibitors, and in particular disclosed are compounds as shown in formula (I), isomers thereof, and pharmaceutically acceptable salts thereof. The IAP inhibitors are drugs for treating cancers, in particular breast cancer.